PCF

1,2-DIACYL-SN-GLYCERO-3-PHOSHOCHOLINE



Chemical Component Summary

Name1,2-DIACYL-SN-GLYCERO-3-PHOSHOCHOLINE
Identifiers[(2R)-2,3-di(hexadecanoyloxy)propyl] 2-trimethylazaniumylethyl phosphate
FormulaC40 H80 N O8 P
Molecular Weight734.039
TypeNON-POLYMER
Isomeric SMILESCCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
InChIInChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1
InChIKeyKILNVBDSWZSGLL-KXQOOQHDSA-N

Chemical Details

Formal Charge0
Atom Count130
Chiral Atom Count1
Bond Count129
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB09114 
NameColfosceril palmitate
Groups
  • investigational
  • withdrawn
  • approved
DescriptionColfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.[A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.
Synonyms
  • Dipalmitoylphosphatidylcholine
  • Palmitate de colfosceril
  • Palmitato de colfoscerilo
  • Colfosceril palmitate
  • Colfoscerili palmitas
Brand Names
  • Exosurf Neonatal
  • Surfaxin
IndicationColfosceril palmitate is indicated for the treatment of respiratory distress syndrome (RDS) in premature infants. The official label is referred as a intratracheal suspension for prophylactic treatment of infants of less than 1350 grams of birth weight under risk of developing RDS, or in infants with birth weight greater than 1350 grams with pulmonary immaturity, or as rescue treatment of infants that already developed RDS.[L1109] The central feature of RDS is a surfactant deficiency due to lung immaturity. This lung condition is more frequently presented due to risk factors like prematurity, delayed lung maturation caused by maternal diabetes or male gender, or surfactant dysfuntion due to perinatal asphyxia, pulmonary infection or delivery without labor.[T70]
Categories
  • Glycerophosphates
  • Glycerophospholipids
  • Lipids
  • Lung Surfactants
  • Membrane Lipids
ATC-CodeR07AA01
CAS number63-89-8

Related Resource References

Resource NameReference
PubChem 452110
ChEMBL CHEMBL1200737
ChEBI CHEBI:72999